ARV-6723 / Arvinas - LARVOL DELTA

ARV-6723: Oral PROTAC HPK1 degrader (GlobeNewswire) - "Initiate enrollment of the Phase 1 clinical trial in patients with advanced solid tumors (3Q 2026)."

New P1 trial • Solid Tumor

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=499 | Recruiting | Sponsor: Arvinas Inc.

Monotherapy • New P1/2 trial • Oncology • Solid Tumor • CTLA4 • LAG3 • PD-1 • PD-L1

ARV-6723: Oral PROTAC HPK1 degrader (The Manila Times) - "Presented preclinical data at the American Association for Cancer Research (AACR) Immuno-Oncology Conference...Robust single-agent antitumor and proinflammatory activity observed in multiple syngeneic tumor models, including those with immunosuppressive TMEs, and showed greater preclinical activity than an investigational HPK1 inhibitor or an anti-PD-1 antibody...Unlike an inhibitor and ICIs, ARV-6723 reversed T-cell exhaustion, reversed the immunosuppressive TME, and boosted innate cell immunity in ICI-(aPD1 and aCTLA4) resistant models....Initiate Phase 1 clinical trial in patients with advanced solid tumors (mid-2026)."

New P1 trial • Preclinical • Solid Tumor

Preclinical antitumor and immunomodulatory activity of ARV-6723, a PROTAC hematopoietic progenitor kinase 1 (HPK1) degrader, versus immune checkpoint inhibitors (ICIs) (AACR 2026) - "ARV-6723 demonstrated greater antitumor activity and proinflammatory, immunomodulatory effects (including increased NK and T cell populations) than single-agent or combination ICI in preclinical models of ICI resistance. These data highlight the potential for ARV-6723 to overcome ICI resistance, supporting its future investigation alone or in combination with ICIs in patients with solid tumors."

Checkpoint inhibition • Immunomodulating • Preclinical • Lung Cancer • Oncology • Solid Tumor • IFNG • IL5 • KRAS • PDX1

Antitumor and immunomodulatory activity of ARV-6723, a PROteoloysis TArgeting Chimera (PROTAC) hematopoietic progenitor kinase 1 (HPK1) degrader, across high- and low-immunogenic solid tumors (AACR-IO 2026) - "In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr C041."

Immunomodulating • IO biomarker • Colon Cancer • Colorectal Cancer • Immunology • Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • Targeted Protein Degradation • IFNG • KRAS • PDX1 • TP53

Anticipated Upcoming Milestones and Expectations (GlobeNewswire) - "ARV-6723: Oral PROTAC HPK1 degrader: Initiate Phase 1 clinical trial in patients with advanced solid tumors (mid-2026, pending regulatory feedback). ARV-6723 is Arvinas’ first immuno-oncology clinical candidate; Present preclinical data evaluating antitumor and unique immunomodulatory activity of ARV-6723 in IO-resistant models compared to standard of care checkpoint inhibition. (1H 2026)....Present preclinical data evaluating the activity and selectivity of novel pan-KRAS degrader in multiple KRAS mutants and differentiation over RAS (ON) or pan-KRAS inhibitors (AACR-RAS, March 2026); Present preclinical data evaluating the efficacy of a novel pan-KRAS degrader in a KRAS syngeneic model, as well as associated immune microenvironment changes (1H 2026)."

New P1 trial • Preclinical • Solid Tumor

ARV-6723: Oral PROTAC HPK1 degrader (Arvinas Press Release) - "Present preclinical data at the Society for Immunotherapy of Cancer Annual Meeting (Nov. 8, 2025); Initiate Phase 1 clinical trial in patients with advanced solid tumors, pending regulatory feedback (2026)."

New P1 trial • Preclinical • Solid Tumor

Preclinical antitumor activity of potent and orally bioavailable PROTAC hematopoietic progenitor kinase 1 (HPK1) degraders as monotherapy or combined with an anti-programmed death-1 (PD-1) antibody (SITC 2025) - "These results support future investigation of PROTAC HPK1 degraders alone or combined with other agents in patients with certain cancers.Ethics Approval Animals were maintained in accordance with the guidelines of the Guide for the Care and Use of Laboratory Animals. All animal research protocol procedures were reviewed and approved by the Arvinas Animal Care and Use Committee."

Monotherapy • Preclinical • Melanoma • Oncology • Solid Tumor • IL2